

Sun Pharmaceutical Industries Ltd.

Sun House, Plot No. 201 B/1,
Western Express Highway, Goregaon (E),
Mumbai - 400 063, Maharashtra, INDIA.
Tel. : (91-22) 4324 4324
Fax : (91-22) 4324 4343
Website : www.sunpharma.com
CIN : L24230GJ1993PLC019050



September 11, 2018

National Stock Exchange of India Ltd,
Exchange Plaza, 5th Floor,
Plot No. C/1, G Block,
Bandra Kurla Complex,
Bandra (East), Mumbai – 400 051.
NSE Code – SUNPHARMA

BSE Ltd,
Market Operations Dept.
P. J. Towers, Dalal Street,
Mumbai - 400 001.
BSE Code– 524715

Sub: Clarification / Confirmation on media report

Dear Sirs,

This is with reference to your email seeking clarification, in terms of the provisions of Regulation 30 of the Listing Regulations, 2015, on the media report, “Sun Pharma's Mohali plant on FDA radar” on www.livemint.com – September 11, 2018. We hereby submit our response as follows:

The US FDA is conducting an inspection of Sun Pharmaceutical Industries Ltd.'s Mohali facility (Punjab, India). The inspection started yesterday, September 10, 2018 and is ongoing.

Further with reference to email query received from NSE, we clarify as follows:

a) Whether such event stated in published news were taking place? If so, you are advised to provide the said information along with the sequence of events in chronological order.

Response – As stated above, the US FDA is conducting an inspection of Sun Pharmaceutical Industries Ltd.'s Mohali facility (Punjab, India). The inspection started yesterday, September 10, 2018 and is ongoing.

b) The material impact of this article on the Company.

Response – No material impact of this article on the Company.

Sun Pharmaceutical Industries Ltd.

Sun House, Plot No. 201 B/1,
Western Express Highway, Goregaon (E),
Mumbai - 400 063, Maharashtra, INDIA.
Tel. : (91-22) 4324 4324
Fax : (91-22) 4324 4343
Website : www.sunpharma.com
CIN : L24230GJ1993PLC019050



c) Whether company are aware of any information that has not been announced to the Exchanges under Regulation 30 of Listing Regulations. If so, you are advised to provide the said information and the reasons for not disclosing the same to the Exchange earlier as required under Regulation 30 of the Listing Regulations.

Response – No

Kindly let us know in case you require any further clarification.

Yours faithfully,

For Sun Pharmaceutical Industries Limited,


Ashok I Bhuta
Compliance Officer

